AADC inhibitor that may increase Fluorodopa F18 bioavailability to the brain by inhibiting peripheral decarboxylase activity.
Source: NLP:fluorodopa f18
Brand names: Fluorodopa F18
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS None None
5 interactions on record
AADC inhibitor that may increase Fluorodopa F18 bioavailability to the brain by inhibiting peripheral decarboxylase activity.
Source: NLP:fluorodopa f18
AADC inhibitor that may increase Fluorodopa F18 bioavailability to the brain by inhibiting peripheral decarboxylase activity.
Source: NLP:fluorodopa f18
May interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.
Source: NLP:fluorodopa f18
Peripheral COMT inhibitors may interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.
Source: NLP:fluorodopa f18
May interfere with Fluorodopa F18 imaging. Consider discontinuing 12 hours before administration if safely possible.
Source: NLP:fluorodopa f18